PURPOSE: The aim of this study was to assess rheumatoid arthritis (RA) synovitis with positron emission tomography (PET) and( 18)F-fluorodeoxyglucose ((18)F-FDG) in comparison with dynamic magnetic resonance imaging (MRI) and ultrasonography (US). METHODS: Sixteen knees in 16 patients with active RA were assessed with PET, MRI and US at baseline and 4 weeks after initiation of anti-TNF-alpha treatment. All studies were performed within 4 days. Visual and semi-quantitative (standardised uptake value, SUV) analyses of the synovial uptake of FDG were performed. The dynamic enhancement rate and the static enhancement were measured after i.v. gadolinium injection and the synovial thickness was measured in the medial, lateral patellar and suprapatellar recesses by US. Serum levels of C-reactive protein (CRP) and metalloproteinase-3 (MMP-3) were also measured. RESULTS: PET was positive in 69% of knees while MRI and US were positive in 69% and 75%. Positivity on one imaging technique was strongly associated with positivity on the other two. PET-positive knees exhibited significantly higher SUVs, higher MRI parameters and greater synovial thickness compared with PET-negative knees, whereas serum CRP and MMP-3 levels were not significantly different. SUVs were significantly correlated with all MRI parameters, with synovial thickness and with serum CRP and MMP-3 levels at baseline. Changes in SUVs after 4 weeks were also correlated with changes in MRI parameters and in serum CRP and MMP-3 levels, but not with changes in synovial thickness. CONCLUSION: (18)F-FDG PET is a unique imaging technique for assessing the metabolic activity of synovitis. The PET findings are correlated with MRI and US assessments of the pannus in RA, as well as with the classical serum parameter of inflammation, CRP, and the synovium-derived parameter, serum MMP-3. Further studies are warranted to establish the place of metabolic imaging of synovitis in RA.
PURPOSE: The aim of this study was to assess rheumatoid arthritis (RA) synovitis with positron emission tomography (PET) and( 18)F-fluorodeoxyglucose ((18)F-FDG) in comparison with dynamic magnetic resonance imaging (MRI) and ultrasonography (US). METHODS: Sixteen knees in 16 patients with active RA were assessed with PET, MRI and US at baseline and 4 weeks after initiation of anti-TNF-alpha treatment. All studies were performed within 4 days. Visual and semi-quantitative (standardised uptake value, SUV) analyses of the synovial uptake of FDG were performed. The dynamic enhancement rate and the static enhancement were measured after i.v. gadolinium injection and the synovial thickness was measured in the medial, lateral patellar and suprapatellar recesses by US. Serum levels of C-reactive protein (CRP) and metalloproteinase-3 (MMP-3) were also measured. RESULTS: PET was positive in 69% of knees while MRI and US were positive in 69% and 75%. Positivity on one imaging technique was strongly associated with positivity on the other two. PET-positive knees exhibited significantly higher SUVs, higher MRI parameters and greater synovial thickness compared with PET-negative knees, whereas serum CRP and MMP-3 levels were not significantly different. SUVs were significantly correlated with all MRI parameters, with synovial thickness and with serum CRP and MMP-3 levels at baseline. Changes in SUVs after 4 weeks were also correlated with changes in MRI parameters and in serum CRP and MMP-3 levels, but not with changes in synovial thickness. CONCLUSION: (18)F-FDG PET is a unique imaging technique for assessing the metabolic activity of synovitis. The PET findings are correlated with MRI and US assessments of the pannus in RA, as well as with the classical serum parameter of inflammation, CRP, and the synovium-derived parameter, serum MMP-3. Further studies are warranted to establish the place of metabolic imaging of synovitis in RA.
Authors: M Ostergaard; M Court-Payen; P Gideon; S Wieslander; M Cortsen; I Lorenzen; O Henriksen Journal: Acta Radiol Date: 1995-01 Impact factor: 1.990
Authors: C Ribbens; M Martin y Porras; N Franchimont; M-J Kaiser; J-M Jaspar; P Damas; F A Houssiau; M G Malaise Journal: Ann Rheum Dis Date: 2002-02 Impact factor: 19.103
Authors: W E Palmer; D I Rosenthal; O I Schoenberg; A J Fischman; L S Simon; R H Rubin; R P Polisson Journal: Radiology Date: 1995-09 Impact factor: 11.105
Authors: Philip Conaghan; Marissa Lassere; Mikkel Østergaard; Charles Peterfy; Fiona McQueen; Philip O'Connor; Paul Bird; Bo Ejbjerg; Mette Klarlund; Ron Shnier; Harry Genant; Paul Emery; John Edmonds Journal: J Rheumatol Date: 2003-06 Impact factor: 4.666
Authors: Anne Roivainen; Riitta Parkkola; Timo Yli-Kerttula; Pertti Lehikoinen; Tapio Viljanen; Timo Möttönen; Pirjo Nuutila; Heikki Minn Journal: Arthritis Rheum Date: 2003-11
Authors: Filomena Mattner; David Linares Bandin; Maria Staykova; Paula Berghofer; Marie Claude Gregoire; Patrice Ballantyne; Mitchell Quinlivan; Susan Fordham; Tien Pham; David O Willenborg; Andrew Katsifis Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-12 Impact factor: 9.236
Authors: Anne Roivainen; Sannamari Hautaniemi; Timo Möttönen; Pirjo Nuutila; Vesa Oikonen; Riitta Parkkola; Luminita Pricop; Rudyard Ress; Nicholas Seneca; Marko Seppänen; Timo Yli-Kerttula Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-15 Impact factor: 9.236
Authors: Mrudula Pullambhatla; Jean Tessier; Graham Beck; Bruno Jedynak; Jens U Wurthner; Martin G Pomper Journal: Am J Nucl Med Mol Imaging Date: 2012-07-10
Authors: Paulo Henrique Rosado-de-Castro; Sergio Augusto Lopes de Souza; Dângelo Alexandre; Lea Mirian Barbosa da Fonseca; Bianca Gutfilen Journal: World J Orthop Date: 2014-07-18